A study found a "substantial deficit" of undiagnosed cancer cases during the COVID-19 pandemic. Completing HBOT appears effective at reducing pain and fibrosis in patients with irradiated breast cancer. A researcher is looking to prove that nebivolol, an FDA-approved drug for high blood pressure, is effective at treating TNBC. Screening and new treatments have led to a US breast cancer mortality rate that is 58% lower than in it was in the mid-1970s. The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer. CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases. The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS. Will HER2CLIMB-02 study data impact the breast cancer landscape? For patients with breast cancer, a regimen of epirubicin followed by adjuvant chemotherapy is associated with worse QOL. Drs. Vishwas Paralkar and Sophia Gayle discuss CBX-15, a novel therapy for triple-negative breast cancer. Dan Forche, CEO of PreludeDx, a leader in precision medicine for early-stage breast cancer, discusses DCISionRT. Kaele Leonard, a pulmonary/critical care fellow who was diagnosed with breast cancer at a young age, discusses her journey. The Fellow on Call: The Heme/Onc Podcast covers HER2-positive breast cancer in part 11 of its series on breast cancer types. The Fellow on Call: The Heme/Onc Podcast switches from localized breast cancers to metastatic subtypes, starting with ER+. The Fellow on Call Podcast shifts its breast cancer focus to the triple-negative subtype. The Fellow on Call Podcast shifts their focus from ER+ to HER+ breast cancer, detailing treatment options, and much more. The Fellow on Call group continues discussing the management of early stage ER+/HER2-breast cancer. Real-world outcomes were comparable to clinical trials in breast cancers with BRCA mutations treated with PARP inhibitors. A cohort analysis found abbreviated breast MRI was an effective for cancer screening in patients with dense breasts. Patients with DCIS breast cancer had "excellent disease control" after lumpectomy and accelerated partial breast irradiation.